I fully agree with your assessment, but watch out for poster creedheed (or something like that) who believes there is no manipulation in the marketplace and in tooth fairies, the Easter Bunny that love if forever....
You clearly know very little about market manipulators or the market itself. If you are that naive and believe there is no manipulation of stock prices, God help you.
The last trade was executed at $6.63 per share and now the bid is for 100 shs. @ $6.56 per share and the ask is $6.60. Why would a seller try to unload at a lower price than the previous sale? This is our biggest problem with our PPS being stalled (stink bids and stink asking PPS)
Vermin shorts hammering away in the last 1/2 hour. Only institutions/hedge funds pull this nasty type trick.
We need some aggressive buying by existing shareholders to counter the vermin day traders and short specialists.
What significant pop are you referring to? The $3.00, $4.00 or $5.00 pop? You can't be talking about a pop less than that are you? Those are the only price increases i think of as pops....................
Asset purchase provides buyer with accelerated tax write-offs for R&D intangibles vs. outright stock purchase that would include all balance sheet items, including some $21 milliion in cash as of 3/31. Presumably, the cash will stay with the company and likely burned on severance, bonus payments and the like with little or nothing additional to the shareholders who lost their savings on this loser. The cumulative losses would only be 10% deductible each year, subject to limits which is small item in the bigger picture. Thus the asset sale that protects the buyer from all other obligations and potential lawsuits.
You statements are correct and I give them a thumb up. But your suggestion that this is a scam would mean the FDA is in on the scam and many others. Very, very improbable. The issue is more on the fact that this is a new uncertain and risky type surgery that already traumatized patients must have their loved ones make during their most difficult times. So I believe it is more about process time and not a scam. Hopefully it will lead to other accidental solutions that result from this beginning started by NVIV science.
I don't disagree at all. None of this financing helps the PPS. I do note that I received two thumbs down for clarifying what actually took place, but some just can't take the truth I guess.
There are two separate offering filings, one for the new shares in connection with the 2016 Warrants covering the 2,146,666 shares and the second offering covering warrants issue back in 2014 I believe. The older warrant had anti-dilution rights and in order to keep them whole an additional 587,950 shares needs to be reserved (registered) for them. In my opinion the management team forgot about the old warrants and the 587,950 additional shares do in fact represent more dilution over and above what we were told with the issuance of the new 2016 warrants. WE NEED SOME GOOD NEWS ON THE PATIENTS PROGRESS AND SQUIRE TRIAL ENROLLMENT.
After a nice start out of the gate this morning to a PPS of $6.24 with heaving buying in the first opening minutes of trading, a 100 share trade dropped the PPS down by $0.18 to $6.06. Trading of this nature will continue to hurt the PPS until major news launches the PPS out of the vermin day and short traders' reach. Can't wait for them to bleed out......................
The biotech company fund raise game in full swing at NVIV. First the promises, clinical trial hype, annual meeting requesting authorization for new shares that ultimately passes. Thereafter, the shelf filing and the company goes into darkness for who knows how long. Incredible this pattern appears time after time and the long term investment suckers just keep on getting hooked.
Lots of questions raised by the company's behavior and failure to be upfront on very important information matters impacting the value of our shares. Very typical of small biotech entities that have the knack of recruiting clueless and unscrupulous executives to run the business. Crazy just like our politics.....
First of all, this filing should be expected as a natural follow-up to the recently approved increase in authorized shares for reasons set forth in the proxy materials. Also, the potential dilution was already factored in the PPS when first announced. We are taken a second hit with this filing due to the vermin hedge funds and day traders who feast on such disclosures at great cost to longer term investors. What is new news if you will is the fact that the older warrants issued several years back had anti-dilution features granting certain rights to those holders to receive incremental share rights as adjusted for whatever dilution their rights experienced. Bottom line is that several hundred thousand additional shares will be exerciseable, again due to the old warrants anti-dilution features, at a cost of under $4.00 per share. Impact should be negligible, but as the professionals play there games, we are taking another hit this morning. What we need is good news and some support from the analyst community about the potential of NVIV value.
Sentiment: Strong Buy